Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoglobulin heavy variable 3-49 is a variable domain segment of the immunoglobulin heavy chain locus, part of the repertoire of variable (V) genes assembled in B cells during V-(D)-J recombination to generate antibody diversity[1][4][6]. This gene segment encodes the variable region of the heavy chain, which, together with associated light chain variable domains, contributes to the antigen-binding site of antibodies, enabling specific recognition of diverse antigens as part of the adaptive immune system. The variable regions also undergo somatic hypermutation after antigen exposure, supporting affinity maturation for improved immune response[1][2][4][6]. IGHV3-49 itself is not considered a classic "therapeutic target" such as a receptor or enzyme, but is one of many germline immunoglobulin variable genes that enable adaptive immunity[1][4][6]. These genes can be subject to investigation in studies of immune repertoire diversity, autoimmunity, or B cell malignancy, but do not function as pharmacological targets[4].
Not applicable (variable regions form part of antigen-binding sites in antibodies; not a therapeutic target mechanism)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immunoglobulin heavy variable 3-49 (IGHV3-49).